Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Review
Nature Reviews Cancer 6, 688–701 (1 September 2006) | doi:10.1038/nrc1958
Polymer conjugates as anticancer nanomedicines
Abstract
The transfer of polymer–protein conjugates into routine clinical use, and the clinical development of polymer–anticancer-drug conjugates, both as single agents and as components of combination therapy, is establishing polymer therapeutics as one of the first classes of anticancer nanomedicines. There is growing optimism that ever more sophisticated polymer-based vectors will be a signficant addition to the armoury currently used for cancer therapy.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
